J&J unveils positive Phase III data for apalutamide in prostate cancer

7 February 2018

Hot on the heels of strong Phase III data for Astellas Pharma (TYO: 4503) and Pfizer’s (NYSE: PFE) Xtandi (enzalutamide) in prostate cancer, US healthcare giant Johnson & Johnson (NYSE: JNJ) has revealed its own set of impressive data in the same indication.

Results from the Phase III SPARTAN trial show that men with non-metastatic castration-resistant prostate cancer (nmCRPC) who were treated with apalutamide had a 72% lower risk of metastasis or death than those who received only placebo.

The therapy prolonged median metastasis-free survival by two years - 40.5 months in the apalutamide group versus 16.2 months in the placebo group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK